• Explore /
  • Poster
  • / PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA).

PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA).

Abstract Poster

Authors

E. Gabriela Chiorean

E. Gabriela Chiorean

University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA

E. Gabriela Chiorean , Paul S. Ritch , David Bing Zhen , Elizabeth Poplin , Ben George , Andrew Eugene Hendifar , Tomislav Dragovich , Andrew L. Coveler , Amy C. Stoll-D'Astice , Stephanie Edwards , Adam Rosenthal , Shelley M. Thorsen , Sunil R. Hingorani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03634332

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS785)

Abstract #

TPS785

Poster Bd #

Q6

Abstract Disclosures

Similar Posters

First Author: David Bing Zhen

First Author: Benjamin Adam Weinberg

First Author: Shipra Gandhi

First Author: Farshid Dayyani